|
Active substance |
letermovir |
|
Holder |
MSD Belgium |
|
Status |
Running |
|
Indication |
prophylaxis of CMV reactivation and disease in paediatric CMV-seropositive recipients [R+] of an allogeneic HSCT. |
|
Public documents Approbation |
|
|
Last update |
08/09/2025 |
Prevymis
Last updated on